Lymphoplasmacytic Lymphoma
Oncology·MeSH: Lymphoma, B-Cell, Marginal Zone
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
3 drugs in development·2 companies·5 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Venetoclax | ENANTA PHARMACEUTICALS INC (ENTA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Lymphoplasmacytic Lymphoma?
BioSniper tracks 3 drugs in development for Lymphoplasmacytic Lymphoma across 2 companies.
How many clinical trials target Lymphoplasmacytic Lymphoma?
There are 5 clinical trials targeting Lymphoplasmacytic Lymphoma tracked by BioSniper.
What is the prevalence of Lymphoplasmacytic Lymphoma?
The estimated prevalence of Lymphoplasmacytic Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Lymphoplasmacytic Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis